Can what’s in your glass influence what’s in your liver? A new cross-sectional pre-pandemic data explores the association between non-skimmed (full-fat and 2%) milk consumption and the prevalence of MAFLD—a liver condition increasingly tied to the global metabolic disease burden.

      Researchers evaluated dietary intake from U.S. adults and analyzed how different types of milk—non-skimmed (full-fat and 2%) vs. skimmed—were associated with MAFLD prevalence.

      MAFLD, recently redefined to replace NAFLD, is linked to obesity, type 2 diabetes, and other features of metabolic syndrome. Unlike its predecessor, MAFLD includes patients with hepatic steatosis and metabolic dysfunction, making its diagnosis more inclusive and clinically relevant.

Key Findings:
• Non-skimmed milk consumers had a significantly higher prevalence of MAFLD compared to those who drank skimmed milk or none at all.
• This association persisted even after adjusting for age, sex, race/ethnicity, socioeconomic status, and other dietary factors.
• Odds of MAFLD increased with higher intake of non-skimmed milk, suggesting a potential dose-response relationship.
• Those with MAFLD also had higher intake of saturated fats, often found in full-fat dairy.

      Why It Matters? This study challenges long-held assumptions that dairy fat is neutral or protective in liver health. As MAFLD affects 1 in 4 adults worldwide, understanding dietary contributors is crucial for prevention and public health strategies.

What’s Next?
• Prospective and mechanistic studies are needed to confirm causality.
• Public health messaging may need to differentiate between dairy types in metabolic disease prevention.
• Personalized dietary guidance should consider fat content and metabolic status.

      Non-skimmed milk may contribute to fatty liver risk—especially in metabolically at-risk individuals. With MAFLD on the rise, what you pour matters more than you think.